Agmon et al., 1994 - Google Patents
Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat.Agmon et al., 1994
View PDF- Document ID
- 8228750567926993674
- Author
- Agmon Y
- Peleg H
- Greenfeld Z
- Rosen S
- Brezis M
- et al.
- Publication year
- Publication venue
- The Journal of clinical investigation
External Links
Snippet
Human radiocontrast nephrotoxicity is predicted by the presence of multiple risk factors, often associated with compromised renal circulation. To produce a simple model of radiocontrast nephropathy, rats were pretreated with indomethacin and N omega-nitro-L …
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide data:image/svg+xml;base64,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 data:image/svg+xml;base64,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 O=[N] 0 title abstract description 39
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl group being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (-N=N-), diazo (=N2), azoxy (>N-O-N< or N(=O)-N<), azido (-N3) or diazoamino (-N=N-N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/026—Measuring blood flow
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Agmon et al. | Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. | |
| Mittal et al. | Nitric oxide modulates hepatic vascular tone in normal rat liver | |
| Tumlin et al. | Pathophysiology of contrast-induced nephropathy | |
| Bakris et al. | Renal hemodynamics in radiocontrast medium-induced renal dysfunction: a role for dopamine-1 receptors | |
| Loureiro-Silva et al. | A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats | |
| Humes et al. | Direct toxic effect of the radiocontrast agent diatrizoate on renal proximal tubule cells | |
| Chang et al. | Enhanced renal prostaglandin production in the dog. II. Effects on intrarenal hemodynamics. | |
| McLenachan et al. | Loss of flow-mediated endothelium-dependent dilation occurs early in the development of atherosclerosis. | |
| Heyman et al. | N-acetylcysteine ameliorates renal microcirculation: studies in rats | |
| Seeliger et al. | Viscosity of contrast media perturbs renal hemodynamics | |
| Rosenberger et al. | Up-regulation of HIF in experimental acute renal failure: evidence for a protective transcriptional response to hypoxia | |
| Deray et al. | Renal effects of radiocontrast agents in rats: a new model of acute renal failure | |
| Corrigan et al. | PAH extraction and estimation of plasma flow in human postischemic acute renal failure | |
| Baile et al. | Effect of contrast media on coronary vascular resistance: contrast-induced coronary vasodilation | |
| Cohen et al. | Renal effects of nitric oxide in endotoxemia | |
| Pastor et al. | Nitric oxide causes hyporeactivity to phenylephrine in isolated perfused livers from endotoxin-treated rats | |
| Nilsson et al. | The novel nitric oxide donor PDNO attenuates ovine ischemia-reperfusion induced renal failure | |
| Kinnala et al. | Pancreas Splanchnic and Pancreatic Tissue Perfusion in Experimental Acute Pancreatitis | |
| Palmes et al. | The endothelin/nitric oxide balance determines small-for-size liver injury after reduced-size rat liver transplantation | |
| Norlén et al. | Intrarenal hemodynamics in the transplanted rat kidney | |
| Levy | Hepatorenal syndrome | |
| Devarajan et al. | Cyclosporine nephrotoxicity: blood volume, sodium conservation, and renal hemodynamics | |
| Genecin et al. | Bile acids do not mediate the hyperdynamic circulation in portal hypertensive rats | |
| Ackerman et al. | Effect of misoprostol on ibuprofen-induced renal dysfunction in patients with decompensated cirrhosis: results of a double-blind placebo-controlled parallel group study | |
| Zook et al. | Mechanisms of the natriuretic and diuretic effects of prostaglandin F2 alpha. |